

TNO:

Initials:

**4.1 ELIGIBILITY AND BASELINE ASSESSMENTS**

1. Has the participant completed the baseline questionnaire?

Yes  No

2. ELIGIBILITY <i>all answers must fall in unshaded boxes</i>	Yes	No
1. Has a designated individual completed and signed an Eligibility Form?	<input type="checkbox"/>	<input type="checkbox"/>
2. Does the participant meet all of the eligibility criteria?	<input type="checkbox"/>	<input type="checkbox"/>

3. If randomised to the intervention arm, would the participant prefer to receive the monthly brief notifications from the HT&Me website via email or text message?

Email  Text

**4.2 STRATIFICATION**

1. Age at trial entry *(defined by date of randomisation)*

<50years  ≥ 50 years

2. Current prescribed adjuvant endocrine therapy

Tamoxifen  Aromatase Inhibitor

3. Treatment complexity: Which of the following has the participant been prescribed, or is planned to receive as part of their breast cancer treatment?

- No chemotherapy, no anti- HER2, no CDK4/6i (i.e., abemaciclib)
- Chemotherapy, no anti-HER2, CDK4/6i (i.e., abemaciclib)
- Chemotherapy, anti-HER2, no CDK4/6i (i.e., abemaciclib)
- Chemotherapy, no anti-HER2, no CDK4/6i (i.e., abemaciclib)
- No chemotherapy, no anti-HER2, CDK4/6i (i.e., abemaciclib)

**TO BE COMPLETED AFTER RANDOMISATION**

**PLEASE TICK THE ARM THE PARTICIPANT HAS BEEN RANDOMISED TO**

HT&Me Intervention   
+usual care

Usual care alone

Form completed by

Printed name:

Signature:

Date signed:

-    -

*N.B. The individual named must be on the delegation log with the assigned responsibility for CRF completion.*